Pre-made Retlirafusp benchmark antibody ( Whole mAb Fusion, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-481
Pre-Made Retlirafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Retlirafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Jiangsu Hengrui Medicine|
|Conditions Active||Pancreatic cancer;Solid tumours;Head and neck squamous cell carcinoma|